El tratamiento temprano del hipertiroidismo reduce la morbilidad y la mortalidad CV en la enfermedad de Graves | oneGRAVESvoice

bienvenido a oneGRAVESvoice

- una comunidad de enfermedades oculares tiroideas y enfermedad de Graves con carga positiva.
  • ¡Únete hoy!

El tratamiento temprano del hipertiroidismo reduce la morbilidad y la mortalidad CV en la enfermedad de Graves


Regardless of the method used, an early and intensive treatment approach to hyperthyroidism in Graves disease is associated with improvements in cardiovascular morbidity and all-cause mortality, according to study results published in The Lancet Diabetes & Endocrinology.

This retrospective cohort study was designed to assess initial therapy choices for patients with Graves disease by identifying associations between treatment method and long-term cardiovascular morbidity and all-cause mortality. From a cohort of patients diagnosed with hyperthyroidism between January 1998 and December 2013 in South Wales, United Kingdom, patients with Graves disease were identified using a thyroid-stimulating hormone (TSH) receptor antibody test register. Participants’ clinical data were linked to study outcomes using the All-Wales Secure Anonymised Information Linkage Databank. The study had no exclusion criteria, and participants were age- and sex-matched 1:4 to a control population within the same database.

 

El tratamiento temprano del hipertiroidismo reduce la morbilidad y la mortalidad CV en la enfermedad de Graves